AddLife AB (publ) (ALIF_B) Q4 2025 Earnings Call

Investor webinar replay

Watch the replay and follow the connected company analysis, news, and investor updates for Addlife Ab Class B.

Watch the replay

Replay transcript excerpt

WEBVTT 00:00:00.031 -- 00:00:04.797 Good morning everyone, and welcome to the AdLive fourth quarter presentation. 00:00:04.797 -- 00:00:09.103 This morning we will take you through the highlights of the quarter, and then of course 00:00:09.103 -- 00:00:14.309 open up for a Q&A session. After that Q&A, we do encourage you to stay 00:00:14.309 -- 00:00:20.097 on because we have recorded a wonderful video of one of our companies, this time Biolin, 00:00:20.097 -- 00:00:23.100 a manufacturer of advanced research instruments. 00:00:23.100 -- 00:00:27.837 So now, let's go. I'm very pleased to note that the AdLab companies were able to wrap 00:00:27.837 -- 00:00:33.164 up 2025 in a good way. We saw continued profit improvement, we saw strong 00:00:33.164 -- 00:00:38.350 profit and strong cash flow. On the EBITDA margin account, we saw 00:00:38.350 -- 00:00:44.678 that Labtech were able to protect the very high level at 14.1% EBITDA 00:00:44.678 -- 00:00:48.963 margin, same as we had in the strong fourth quarter of last year. 00:00:48.963 -- 00:00:54.605 And on the Medtech side, it improved to 12% compared to 11.6%. 00:00:54.605 -- 00:00:58.088 in the corresponding quarter of last year. 00:00:58.088 -- 00:01:03.452 Overall, we saw healthy customer demand in our markets, but of course currency 00:01:03.452 -- 00:01:08.597 effects impacted our sales growth, but the currency adjusted sales 00:01:08.597 -- 00:01:12.280 increased by 2% in the quarter. 00:01:12.280 -- 00:01:17.404 We are working diligently with profit improvement initiatives, and this is one 00:01:17.404 -- 00:01:22.549 of the core parts of our business model. We have seen for many quarters 00:01:22.549 -- 00:01:28.911 now a continuous improvement, and we do expect that to continue in the future as well. 00:01:28....